A long-term analysis evaluating the cost-effectiveness of biphasic insulin lispro mix 75/25 and mix 50/50 versus long-acting basal insulin analogs in the United States

References

• Zhang P, Zhang X, Brown J, et al. Global healthcare expenditure on diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010;87:293-301
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Economic costs of diabetes in the U.S. In 2007. Diabetes Care 2008;31:596-615
   Google Scholar
• U.K. Prospective Diabetes Study Group. U.K. Prospective Diabetes Study 16: overview of 6 years’ therapy of type II diabetes: a progressive disease. Diabetes 1995;44:1249-58
   PubMed Web of Science ®Google Scholar
• Sarpong E, Miller E. Agency for Healthcare Research and Quality Statistical Brief #293: trends in the pharmaceutical treatment of diabetes: a comparison of utilization and expenditures, 1997 to 2007. 2010. http://www.meps.ahrq.gov/mepsweb/data_files/publications/st293/stat293.shtml. Accessed March 9, 2012
   Google Scholar
• Bonafede MM, Kalsekar A, Pawaskar M, et al. A retrospective database analysis of insulin use patterns in insulin-naïve patients with type 2 diabetes initiating basal insulin or mixtures. Patient Prefer Adherence 2010;4:147-56
   PubMed Web of Science ®Google Scholar
• Valentine WJ, Palmer AJ, Erny-Albrecht KM, et al. Cost-effectiveness of basal insulin from a US health system perspective: comparative analyses of detemir, glargine, and NPH. Adv Ther 2006;23:191-207
   PubMed Web of Science ®Google Scholar
• Pscherer S, Dietrich ES, Dippel FW, et al. Comparison of one-year costs of type 2 diabetes treatment with insulin glargine or insulin detemir in a basal supported oral therapy (BOT) in Germany. Int J Clin Pharmacol Ther 2010;48:129-37
   PubMedGoogle Scholar
• Guillermin AL, Samyshkin Y, Wright D, et al. Modeling the lifetime costs of insulin glargine and insulin detemir in type 1 and type 2 diabetes patients in Canada: a meta-analysis and a cost-minimization analysis. J Med Econ 2011;14:207-16
   PubMedGoogle Scholar
• Tunis SL, Minshall ME, Conner C, et al. Cost-effectiveness of insulin detemir compared to NPH insulin for type 1 and type 2 diabetes mellitus in the Canadian payer setting: modeling analysis. Curr Med Res Opin 2009;25:1273-84
   PubMed Web of Science ®Google Scholar
• Brändle M, Azoulay M, Greiner RA. Cost-effectiveness and cost-utility of insulin glargine compared with NPH insulin based on a 10-year simulation of long-term complications with the Diabetes Mellitus Model in patients with type 2 diabetes in Switzerland. Int J Clin Pharmacol Ther 2007;45:203-20
   PubMed Web of Science ®Google Scholar
• Palmer AJ, Roze S, Valentine WJ, et al. The CORE Diabetes Model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin 2004;20(1 Suppl):S5-26
   PubMed Web of Science ®Google Scholar
• Palmer AJ, Roze S, Valentine WJ, et al. Validation of the CORE Diabetes Model against epidemiological and clinical studies. Curr Med Res Opin 2004;20(1 Suppl):S27-40
   PubMed Web of Science ®Google Scholar
• Nathan DM, Buse JB, Davidson MB, et al; American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32:193-203
   PubMed Web of Science ®Google Scholar
• Tunis SL, Minshall ME. Self-monitoring of blood glucose in type 2 diabetes: cost-effectiveness in the United States. Am J Manag Care 2008;14:131-40
   PubMed Web of Science ®Google Scholar
• Jones S, Benroubi M, Castell C, et al. Characteristics of patients with type 2 diabetes mellitus initiating insulin therapy: baseline data from the INSTIGATE study. Curr Med Res Opin 2009;25:691-700
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Cigarette smoking among adults—United States, 2004. JAMA 2006;295:749-51
   Google Scholar
• National Institute on Alcohol Abuse and Alcoholism (NIAAA). NIAAA 2006 http://www.niaaa.nih.gov/Resources/GraphicsGallery/consfigs4text.htm. Accessed March 9, 2012
   Google Scholar
• National Diabetes Data Group; National Institutes of Health; National Institute of Diabetes and Digestive and Kidney Diseases. Diabetes in America. 2nd ed. NIH Publication No. 95–1468, 1995
   Google Scholar
• Kannel WB, Wolf PA, Benjamin EJ, et al. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 1998;82:2N-9N
   PubMed Web of Science ®Google Scholar
• Phillips SJ, Whisnant JP, O’Fallon WM, et al. Prevalence of cardiovascular disease and diabetes mellitus in residents of Rochester, Minnesota. Mayo Clin Proc 1990;65:344-59
   PubMed Web of Science ®Google Scholar
• Harris MI. Health care and health status and outcomes for patients with type 2 diabetes. Diabetes Care 2000;23:754-8
   PubMed Web of Science ®Google Scholar
• Brandle M, Zhou H, Smith BR, et al. The direct medical cost of type 2 diabetes. Diabetes Care 2003;26:2300-4
   PubMed Web of Science ®Google Scholar
• Moss SE, Klein R, Klein BE. The prevalence and incidence of lower extremity amputation in a diabetic population. Arch Intern Med 1992;152:610-6
   PubMed Web of Science ®Google Scholar
• Qayyum R, Bolen S, Maruthur N, et al. Systematic review: comparative effectiveness and safety of premixed insulin analogues in type 2 diabetes. Ann Intern Med 2008;149:549-59
   PubMed Web of Science ®Google Scholar
• O'Brien JA, Patrick AR, Caro J. Estimates of direct medical costs for microvascular and macrovascular complications resulting from type 2 diabetes mellitus in the United States in 2000. Clin Ther 2003;25:1017-38
   PubMed Web of Science ®Google Scholar
• Pelletier EM, Smith PJ, Boye KS, et al. Direct medical costs for type 2 diabetes mellitus complications in the US commercial payer setting: a resource for economic research. Appl Health Econ Health Policy 2008;6:103-12
   PubMedGoogle Scholar
• World Health Organization Collaborating Centre for Drug Statistics Methodology. Anatomical Therapeutic Chemical/Defined Daily Dose Index 2010. http://www.whocc.no/atc_ddd_index/?code=A10AE. Accessed May 11, 2010
   Google Scholar
• Gold MR, Siegel JE, Russell LB, et al., eds. Cost-effectiveness in health and medicine. New York, NY: Oxford University Press, 1996
   Google Scholar
• Levy AR, Christensen TL, Johnson JA. Utility values for symptomatic non-severe hypoglycaemia elicited from persons with and without diabetes in Canada and the United Kingdom. Health Qual Life Outcomes 2008;29:73
   Google Scholar
• Clarke P, Gray A, Holman R. Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making 2002;22:340-9
   PubMed Web of Science ®Google Scholar
• Coffey JT, Brandle M, Zhou H, et al. Valuing health-related quality of life in diabetes. Diabetes Care 2002;25:2238-43
   PubMed Web of Science ®Google Scholar
• Ilag LL, Kerr L, Malone JK, et al. Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes: an evidence-based comparison. Clin Ther 2007;29:1254-70
   Web of Science ®Google Scholar
• Lasserson DS, Glasziou P, Perera R, et al. Optimal insulin regimens in type 2 diabetes mellitus: systematic review and meta-analyses. Diabetologia 2009;52:1990-2000
   PubMed Web of Science ®Google Scholar
• Karter AJ, Parker MM, Moffet HH, et al. Longitudinal study of new and prevalent use of self-monitoring of blood glucose. Diabetes Care 2006;29(8):1757-63
   PubMedGoogle Scholar